Diagnosis and Management of Clostridium difficile Infection

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 1, 2015, Pages 31-43

  Korman, Tony M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

antibiotic associated colitis; Clostridium difficile; fecal microbiota transplantation; fidaxomicin; pseudomembranous colitis; toxic megacolcon

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CADAZOLID; DRUG THERAPY; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; NITAZOXANIDE; NUCLEIC ACID; PROBIOTIC AGENT; SUROTOMYCIN; TOXIN; VANCOMYCIN;

ADULT; ALGORITHM; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BIOLOGICAL THERAPY; CELL CULTURE CYTOTOXICITY NEUTRALIZATION ASSAY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM INFECTIONS; COLON RESECTION; CROSS INFECTION; CYTOTOXICITY ASSAY; DEFINED BACTERIOTHERAPY; DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DONOR; DRUG EFFECTS; DRUG THERAPY; ENDOSCOPY; ENZYME IMMUNOASSAY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; ILEOSTOMY; IMMUNOTHERAPY; INTRACOLONIC DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; MICROBIOLOGY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RECURRENT INFECTION; THERAPY; TOXIGENIC CULTURE; TRANSPLANTATION; VALIDATION STUDY;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIAGNOSIS; DRUG EFFECTS; DRUG THERAPY; HUMANS; MICROBIOLOGY; PATHOGENICITY; RECURRENCE; THERAPEUTIC USE;

EID: 84964282455     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1398741     Document Type: Article

References (220)

1. Young V. B.; Hanna P. C. Overlapping roles for toxins in Clostridium difficile infection. J Infect Dis: 2014; 209 1 9 11
2. Lyras D.; O'Connor J. R.; Howarth P. M.; et al. Toxin B is essential for virulence of Clostridium difficile. Nature: 2009; 458 7242 1176 1179
3. Kuehne S. A.; Cartman S. T.; Heap J. T.; Kelly M. L.; Cockayne A.; Minton N. P. The role of toxin A and toxin B in Clostridium difficile infection. Nature: 2010; 467 7316 711 713
4. Kuehne S. A.; Collery M. M.; Kelly M. L.; Cartman S. T.; Cockayne A.; Minton N. P. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis: 2014; 209 1 83 86
5. Freeman J.; Bauer M. P.; Baines S. D.; et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev: 2010; 23 3 529 549
6. Pépin J.; Valiquette L.; Alary M-E.; et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ: 2004; 171 5 466 472
7. Loo V. G.; Bourgault A-M, Poirier L.; et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med: 2011; 365 18 1693 1703
8. McDonald L. C.; Killgore G. E.; Thompson A.; et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med: 2005; 353 23 2433 2441
9. Warny M.; Pepin J.; Fang A.; et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet: 2005; 366 9491 1079 1084
10. Carter G. P.; Douce G. R.; Govind R.; et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog: 2011; 7 10 e1002317
11. Magill S. S.; Edwards J. R.; Bamberg W.; et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med: 2014; 370 13 1198 1208
12. Miller B. A.; Chen L. F.; Sexton D. J.; Anderson D. J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol: 2011; 32 4 387 390
13. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States; 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/
14. Dubberke E. R.; Olsen M. A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis: 2012; 55 02 S88 S92
15. Hensgens M. PM, Keessen E. C.; Squire M. M.; et al. European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect: 2012; 18 7 635 645
16. Khanna S.; Pardi D. S.; Aronson S. L.; et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol: 2012; 107 1 89 95
17. Khanna S.; Pardi D. S. Community-acquired Clostridium difficile infection: an emerging entity. Clin Infect Dis: 2012; 55 12 1741 1742
18. Lessa F. C.; Gould C. V.; McDonald L. C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis: 2012; 55 02 S65 S70
19. Lessa F. C. Community-associated Clostridium difficile infection: how real is it? Anaerobe: 2013; 24 121 123
20. Slimings C.; Riley T. V. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother: 2014; 69 4 881 891
21. Brown K. A.; Khanafer N.; Daneman N.; Fisman D. N. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother: 2013; 57 5 2326 2332
22. Deshpande A.; Pasupuleti V.; Thota P.; et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother: 2013; 68 9 1951 1961
23. Britton R. A.; Young V. B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology: 2014; 146 6 1547 1553
24. Hensgens M. PM, Goorhuis A.; Dekkers O. M.; Kuijper E. J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother: 2012; 67 3 742 748
25. Janarthanan S.; Ditah I.; Adler D. G.; Ehrinpreis M. N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol: 2012; 107 7 1001 1010
26. Vonberg R-P, Kuijper E. J.; Wilcox M. H.; et al. European C difficile-Infection Control Group; European Centre for Disease Prevention and Control (ECDC). Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect: 2008; 14 05 2 20
27. Dubberke E. R.; Carling P.; Carrico R.; et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol: 2014; 35 6 628 645
28. Edmonds S. L.; Zapka C.; Kasper D.; et al. Effectiveness of hand hygiene for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol: 2013; 34 3 302 305
29. McFarland L. V.; Mulligan M. E.; Kwok R. Y.; Stamm W. E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med: 1989; 320 4 204 210
30. Weber D. J.; Anderson D. J.; Sexton D. J.; Rutala W. A. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control: 2013; 41 (5, Suppl): S105 S110
31. Wilcox M. H.; Fraise A. P.; Bradley C. R.; Walker J.; Finch R. G. Sporicides for Clostridium difficile: the devil is in the detail. J Hosp Infect: 2011; 77 3 187 188
32. Feazel L. M.; Malhotra A.; Perencevich E. N.; Kaboli P.; Diekema D. J.; Schweizer M. L. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother: 2014; 69 7 1748 1754
33. Wilcox M. H.; Shetty N.; Fawley W. N.; et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis: 2012; 55 8 1056 1063
34. Debast S. B.; Bauer M. P.; Kuijper E. J.; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect: 2014; 20 02 1 26
35. Bartlett J. G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med: 2002; 346 5 334 339
36. Kelly C. P.; LaMont J. T. Clostridium difficile-more difficult than ever. N Engl J Med: 2008; 359 18 1932 1940
37. Walker A. S.; Eyre D. W.; Wyllie D. H.; et al. Infections in Oxfordshire Research Database. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis: 2013; 56 11 1589 1600
38. Aronoff D. M. Editorial commentary: host-pathogen interactions in Clostridium difficile infection: it takes two to tango. Clin Infect Dis: 2014; 58 10 1401 1403
39. Kyne L.; Warny M.; Qamar A.; Kelly C. P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med: 2000; 342 6 390 397
40. Alasmari F.; Seiler S. M.; Hink T.; Burnham C-AD, Dubberke E. R. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis: 2014; 59 2 216 222
41. Riggs M. M.; Sethi A. K.; Zabarsky T. F.; Eckstein E. C.; Jump R. LP, Donskey C. J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis: 2007; 45 8 992 998
42. Curry S. R.; Muto C. A.; Schlackman J. L.; et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis: 2013; 57 8 1094 1102
43. Burnham C-AD, Carroll K. C. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev: 2013; 26 3 604 630
44. Crobach M. JT, Dekkers O. M.; Wilcox M. H.; Kuijper E. J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect: 2009; 15 12 1053 1066
45. Brecher S. M.; Novak-Weekley S. M.; Nagy E. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis: 2013; 57 8 1175 1181
46. Ticehurst J. R.; Aird D. Z.; Dam L. M.; Borek A. P.; Hargrove J. T.; Carroll K. C. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol: 2006; 44 3 1145 1149
47. Aichinger E.; Schleck C. D.; Harmsen W. S.; Nyre L. M.; Patel R. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol: 2008; 46 11 3795 3797
48. Luo R. F.; Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol: 2010; 48 10 3738 3741
49. Cohen S. H.; Gerding D. N.; Johnson S.; et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol: 2010; 31 5 431 455
50. Planche T.; Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol: 2011; 64 1 1 5
51. Eastwood K.; Else P.; Charlett A.; Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol: 2009; 47 10 3211 3217
52. Carroll K. C. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe: 2011; 17 4 170 174
53. Planche T. D.; Davies K. A.; Coen P. G.; et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis: 2013; 13 11 936 945
54. Goldenberg S. D.; Gumban M.; Hall A.; Patel A.; French G. L. Lack of effect of strain type on detection of toxigenic Clostridium difficile by glutamate dehydrogenase and polymerase chain reaction. Diagn Microbiol Infect Dis: 2011; 70 3 417 419
55. Carman R. J.; Wickham K. N.; Chen L.; et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J Clin Microbiol: 2012; 50 4 1425 1426
56. Shetty N.; Wren M. WD, Coen P. G. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. J Hosp Infect: 2011; 77 1 1 6
57. Novak-Weekley S. M.; Marlowe E. M.; Miller J. M.; et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol: 2010; 48 3 889 893
58. Kok J.; Wang Q.; Thomas L. C.; Gilbert G. L. Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution. J Clin Microbiol: 2011; 49 10 3719 3721
59. Lim S. K.; Stuart R. L.; Mackin K. E.; et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis: 2014; 58 12 1723 1730
60. Deshpande A.; Pasupuleti V.; Rolston D. DK.; et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis. Clin Infect Dis: 2011; 53 7 e81 e90
61. Wilcox M. H.; Planche T.; Fang F. C.; Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol: 2010; 48 12 4347 4353
62. Surawicz C. M.; Brandt L. J.; Binion D. G.; et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol: 2013; 108 4 478 498, quiz 499
63. Longtin Y.; Trottier S.; Brochu G.; et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis: 2013; 56 1 67 73
64. Goldenberg S. D.; Price N. M.; Tucker D.; Wade P.; French G. L. Mandatory reporting and improvements in diagnosing Clostridium difficile infection: an incompatible dichotomy? J Infect: 2011; 62 5 363 370
65. Gould C. V.; Edwards J. R.; Cohen J.; et al. Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis: 2013; 57 9 1304 1307
66. Larson A. M.; Fung A. M.; Fang F. C. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol: 2010; 48 1 124 130
67. Babady N. E.; Stiles J.; Ruggiero P.; et al. Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol: 2010; 48 12 4519 4524
68. Tedesco F. J. Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology: 1979; 77 2 295 297
69. Tedesco F. J.; Corless J. K.; Brownstein R. E. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology: 1982; 83 6 1259 1260
70. Johal S. S.; Hammond J.; Solomon K.; James P. D.; Mahida Y. R. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut: 2004; 53 5 673 677
71. Fekety R.; Shah A. B. Diagnosis and treatment of Clostridium difficile colitis. JAMA: 1993; 269 1 71 75
72. Froberg M. K.; Palavecino E.; Dykoski R.; Gerding D. N.; Peterson L. R.; Johnson S. Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis: 2004; 39 5 747 750
73. Price A. B.; Davies D. R. Pseudomembranous colitis. J Clin Pathol: 1977; 30 1 1 12
74. Gerding D. N.; Olson M. M.; Peterson L. R.; et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med: 1986; 146 1 95 100
75. Ananthakrishnan A. N.; Binion D. G. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol: 2010; 4 5 589 600
76. Goodhand J. R.; Alazawi W.; Rampton D. S. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther: 2011; 33 4 428 441
77. Kawamoto S.; Horton K. M.; Fishman E. K. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics: 1999; 19 4 887 897
78. Sheth S. G.; LaMont J. T. Toxic megacolon. Lancet: 1998; 351 9101 509 513
79. Valiquette L.; Pépin J.; Do X-V.; et al. Prediction of complicated Clostridium difficile infection by pleural effusion and increased wall thickness on computed tomography. Clin Infect Dis: 2009; 49 4 554 560
80. Boland G. W.; Lee M. J.; Cats A.; Mueller P. R. Pseudomembranous colitis: diagnostic sensitivity of the abdominal plain radiograph. Clin Radiol: 1994; 49 7 473 475
81. Boland G. W.; Lee M. J.; Cats A. M.; Gaa J. A.; Saini S.; Mueller P. R. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology: 1994; 191 1 103 106
82. Ash L.; Baker M. E.; O'Malley C. M. Jr, Gordon S. M.; Delaney C. P.; Obuchowski N. A. Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol: 2006; 186 5 1393 1400
83. Kirkpatrick I. D.; Greenberg H. M. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol: 2001; 176 3 635 639
84. Garey K. W.; Sethi S.; Yadav Y.; DuPont H. L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect: 2008; 70 4 298 304
85. Mullane K. M.; Miller M. A.; Weiss K.; et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis: 2011; 53 5 440 447 (Erratum in Clin Infect Dis. 2011;53(12):1312)
86. Teasley D. G.; Gerding D. N.; Olson M. M.; et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet: 1983; 2 8358 1043 1046
87. Koo H. L.; Koo D. C.; Musher D. M.; DuPont H. L. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis: 2009; 48 5 598 605
88. Chaparro-Rojas F.; Mullane K. M. Emerging therapies for Clostridium difficile infection-focus on fidaxomicin. Infect Drug Resist: 2013; 6 41 53
89. Gerding D. N. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis: 2005; 40 11 1598 1600
90. Drekonja D. M.; Butler M.; MacDonald R.; et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med: 2011; 155 12 839 847
91. Nelson R. L.; Kelsey P.; Leeman H.; et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev: 2011; 9 CD004610. doi: 10.1002/14651858.CD004610.pub4
92. Wilcox M. H. Editorial Commentary: the trials and tribulations of treating Clostridium difficile infection-one step backward, one step forward, but still progress. Clin Infect Dis: 2014; 59 3 355 357
93. Bartlett J. G. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis: 2008; 46 10 1489 1492
94. Tran M-CN, Claros M. C.; Goldstein E. JC. Therapy of Clostridium difficile infection: perspectives on a changing paradigm. Expert Opin Pharmacother: 2013; 14 17 2375 2386
95. Musher D. M.; Aslam S.; Logan N.; et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis: 2005; 40 11 1586 1590
96. Pepin J.; Alary M-E, Valiquette L.; et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis: 2005; 40 11 1591 1597
97. Al-Nassir W. N.; Sethi A. K.; Nerandzic M. M.; Bobulsky G. S.; Jump R. LP, Donskey C. J. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis: 2008; 47 1 56 62
98. Zar F. A.; Bakkanagari S. R.; Moorthi K. MLST, Davis M. B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis: 2007; 45 3 302 307
99. Modena S.; Gollamudi S.; Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol: 2006; 40 1 49 54
100. Wilcox M. H.; Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother: 1995; 36 4 673 679
101. Johnson S.; Louie T. J.; Gerding D. N.; et al. Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis: 2014; 59 3 345 354
102. Bolton R. P.; Culshaw M. A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut: 1986; 27 10 1169 1172
103. Johnson S.; Homann S. R.; Bettin K. M.; et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med: 1992; 117 4 297 302
104. Baines S. D.; O'Connor R.; Freeman J.; et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother: 2008; 62 5 1046 1052
105. Hecht D. W.; Galang M. A.; Sambol S. P.; Osmolski J. R.; Johnson S.; Gerding D. N. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother: 2007; 51 8 2716 2719
106. Sears P.; Crook D. W.; Louie T. J.; Miller M. A.; Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis: 2012; 55 02 S116 S120
107. Weiss K.; Allgren R. L.; Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clin Infect Dis: 2012; 55 02 S110 S115
108. Louie T. J.; Miller M. A.; Mullane K. M.; et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med: 2011; 364 5 422 431
109. Cornely O. A.; Crook D. W.; Esposito R.; et al. OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis: 2012; 12 4 281 289
110. Cornely O. A.; Nathwani D.; Ivanescu C.; Odufowora-Sita O.; Retsa P.; Odeyemi I. AO. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother: 2014; 69 11 2892 2900
111. Petrella L. A.; Sambol S. P.; Cheknis A.; et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis: 2012; 55 3 351 357
112. Babakhani F.; Bouillaut L.; Sears P.; Sims C.; Gomez A.; Sonenshein A. L. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother: 2013; 68 3 515 522
113. Babakhani F.; Bouillaut L.; Gomez A.; Sears P.; Nguyen L.; Sonenshein A. L. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis: 2012; 55 02 S162 S169
114. Tannock G. W.; Munro K.; Taylor C.; et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology: 2010; 156 Pt 11 3354 3359
115. Louie T. J.; Cannon K.; Byrne B.; et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis: 2012; 55 02 S132 S142
116. Louie T. J.; Emery J.; Krulicki W.; Byrne B.; Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother: 2009; 53 1 261 263
117. Eyre D. W.; Babakhani F.; Griffiths D.; et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis: 2014; 209 9 1446 1451
118. Nerandzic M. M.; Mullane K.; Miller M. A.; Babakhani F.; Donskey C. J. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis: 2012; 55 02 S121 S126
119. Bartsch S. M.; Umscheid C. A.; Fishman N.; Lee B. Y. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis: 2013; 57 4 555 561
120. Nathwani D.; Cornely O. A.; Van Engen A. K.; Odufowora-Sita O.; Retsa P.; Odeyemi I. AO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother: 2014; 69 11 2901 2912
121. Musher D. M.; Logan N.; Bressler A. M.; Johnson D. P.; Rossignol J. F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis: 2009; 48 4 e41 e46
122. Zucca M.; Scutera S.; Savoia D. Novel avenues for Clostridium difficile infection drug discovery. Expert Opin Drug Discov: 2013; 8 4 459 477
123. Abou Chakra C. N.; Pepin J.; Sirard S.; Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE: 2014; 9 6 e98400
124. Bauer M. P.; Hensgens M. PM, Miller M. A.; et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis: 2012; 55 02 S149 S153
125. Miller M. A.; Louie T.; Mullane K.; et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis: 2013; 13 148
126. Abou Chakra C. N.; Pepin J.; Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE: 2012; 7 1 e30258
127. Goorhuis A.; Bakker D.; Corver J.; et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis: 2008; 47 9 1162 1170
128. Miller M.; Gravel D.; Mulvey M.; et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis: 2010; 50 2 194 201
129. Gerding D. N.; Johnson S. Does infection with specific Clostridium difficile strains or clades influence clinical outcome? Clin Infect Dis: 2013; 56 11 1601 1603
130. Walk S. T.; Micic D.; Galecki A. T.; Young V. B.; Aronoff D. M. Understanding increased mortality in Clostridium difficile-infected older adults. Clin Infect Dis: 2013; 57 4 625 626
131. See I.; Mu Y.; Cohen J.; et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis: 2014; 58 10 1394 1400
132. Johnson S. Editorial commentary: changing epidemiology of Clostridium difficile and emergence of new virulent strains. Clin Infect Dis: 2014; 58 12 1731 1733
133. Fekety R.; Silva J.; Kauffman C.; Buggy B.; Deery H. G. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med: 1989; 86 1 15 19
134. Friedenberg F.; Fernandez A.; Kaul V.; Niami P.; Levine G. M. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum: 2001; 44 8 1176 1180
135. Bass S. N.; Bauer S. R.; Neuner E. A.; Lam S. W. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. J Hosp Infect: 2013; 85 1 22 27
136. Wenisch J. M.; Schmid D.; Kuo H-W.; et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother: 2012; 56 4 1974 1978
137. Tedesco F.; Markham R.; Gurwith M.; Christie D.; Bartlett J. G. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet: 1978; 2 8083 226 228
138. Aldape M. J.; Heeney D. D.; Bryant A. E.; Stevens D. L. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother: 2015; 70 153 159
139. Nord C. E.; Sillerström E.; Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother: 2006; 50 10 3375 3380
140. Jump R. LP, Li Y.; Pultz M. J.; Kypriotakis G.; Donskey C. J. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother: 2011; 55 2 546 549
141. Herpers B. L.; Vlaminckx B.; Burkhardt O.; et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis: 2009; 48 12 1732 1735
142. Thomas A.; Khan F.; Uddin N.; Wallace M. R. Tigecycline for severe Clostridium difficile infection. Int J Infect Dis: 2014; 26 171 172
143. Cheong E. YL, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust: 2011; 194 7 374 375
144. Apisarnthanarak A.; Razavi B.; Mundy L. M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis: 2002; 35 6 690 696
145. Kim P. K.; Huh H. C.; Cohen H. W.; et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt): 2013; 14 6 532 539
146. Saffouri G.; Khanna S.; Estes L.; Pardi D. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol: 2014; 109 6 924 925
147. Bhangu A.; Nepogodiev D.; Gupta A.; Torrance A.; Singh P.; West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg: 2012; 99 11 1501 1513
148. Lamontagne F.; Labbé A-C, Haeck O.; et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg: 2007; 245 2 267 272
149. Stewart D. B.; Hollenbeak C. S.; Wilson M. Z. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis: 2013; 15 7 798 804
150. Noblett S. E.; Welfare M.; Seymour K. The role of surgery in Clostridium difficile colitis. BMJ: 2009; 338 b1563
151. Karmali S.; Laffin M.; de Gara C. CAGS Clinical Practice Committee report: the science of Clostridium difficile and surgery. Can J Surg: 2013; 56 6 367 371
152. Ferrada P.; Velopulos C. G.; Sultan S.; et al. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg: 2014; 76 6 1484 1493
153. Sailhamer E. A.; Carson K.; Chang Y.; et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg: 2009; 144 5 433 439, discussion 439-440
154. Neal M. D.; Alverdy J. C.; Hall D. E.; Simmons R. L.; Zuckerbraun B. S. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg: 2011; 254 3 423 427, discussion 427-429
155. Brown C. J.; Boutros M.; Morris A.; Divino C. M.; CAGS/ACS Evidence Based Reviews in Surgery Group. CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease? Can J Surg: 2014; 57 3 214 216
156. McFarland L. V.; Surawicz C. M.; Greenberg R. N.; et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA: 1994; 271 24 1913 1918
157. McFarland L. V.; Elmer G. W.; Surawicz C. M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol: 2002; 97 7 1769 1775
158. Cornely O. A.; Miller M. A.; Louie T. J.; Crook D. W.; Gorbach S. L. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis: 2012; 55 02 S154 S161
159. Tedesco F. J.; Gordon D.; Fortson W. C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol: 1985; 80 11 867 868
160. Johnson S.; Gerding D. N. Fidaxomicin chaser regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis: 2013; 56 2 309 310
161. Ojaimi S.; Korman T. M. Rifaximin. In: Grayson M.; Crowe S.; McCarthy J.; et al, eds. Kucers' the Use of Antibiotics: American Society for Microbiology and Hodder Arnold; 2010
162. Johnson S.; Schriever C.; Galang M.; Kelly C. P.; Gerding D. N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis: 2007; 44 6 846 848
163. Garey K. W.; Jiang Z. D.; Bellard A.; Dupont H. L. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol: 2009; 43 1 91 93
164. Rubin D. T.; Sohi S.; Glathar M.; Thomas T.; Yadron N.; Surma B. L. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract: 2011; 2011 106978
165. Mattila E.; Arkkila P.; Mattila P. S.; Tarkka E.; Tissari P.; Anttila V-J. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther: 2013; 37 1 122 128
166. Garey K. W.; Ghantoji S. S.; Shah D. N.; et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother: 2011; 66 12 2850 2855
167. O'Connor J. R.; Galang M. A.; Sambol S. P.; et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother: 2008; 52 8 2813 2817
168. Curry S. R.; Marsh J. W.; Shutt K. A.; et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis: 2009; 48 4 425 429
169. Huang J. S.; Jiang Z. D.; Garey K. W.; Lasco T.; Dupont H. L. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother: 2013; 57 6 2690 2693
170. Miller M. A.; Blanchette R.; Spigaglia P.; Barbanti F.; Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol: 2011; 49 12 4319 4321
171. Schubert A. M.; Rogers M. AM, Ring C.; et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio: 2014; 5 3 e01021 e14
172. Chang J. Y.; Antonopoulos D. A.; Kalra A.; et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis: 2008; 197 3 435 438
173. Martin J.; Mawer D.; Wilcox M. H. Clostridium difficile: biological therapies. Curr Opin Infect Dis: 2013; 26 5 454 460
174. Shim J. K.; Johnson S.; Samore M. H.; Bliss D. Z.; Gerding D. N. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet: 1998; 351 9103 633 636
175. Seal D.; Borriello S. P.; Barclay F.; Welch A.; Piper M.; Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol: 1987; 6 1 51 53
176. Villano S. A.; Seiberling M.; Tatarowicz W.; Monnot-Chase E.; Gerding D. N. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother: 2012; 56 10 5224 5229
177. Villano S. A.; Armstrong J.; Meyer T.; et al. Therapeutic Use of an Oral Suspension of VP20621, Spores of a Non-Toxigenic Clostridium difficile (NTCD) Strain, for Prevention of Recurrence of C. difficile Infection (CDI). ID Week 2013. Late Breaker Oral Abstracts LB-7. September 28, 2013:169b
178. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe: 2009; 15 6 281 284
179. Tasteyre A.; Barc M-C, Karjalainen T.; Bourlioux P.; Collignon A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog: 2002; 32 5 219 225
180. Castagliuolo I.; Riegler M. F.; Valenick L.; LaMont J. T.; Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun: 1999; 67 1 302 307
181. Chen X.; Kokkotou E. G.; Mustafa N.; et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem: 2006; 281 34 24449 24454
182. Qamar A.; Aboudola S.; Warny M.; et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun: 2001; 69 4 2762 2765
183. Pillai A.; Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev: 2008; 1 1 CD004611
184. Goldenberg J. Z.; Ma S. S.; Saxton J. D.; et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev: 2013; 5 CD006095
185. Johnston B. C.; Ma S. SY, Goldenberg J. Z.; et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med: 2012; 157 12 878 888
186. Allen S. J.; Wareham K.; Bradley C.; et al. A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. BMC Infect Dis: 2012; 12 108
187. Allen S. J.; Wareham K.; Wang D.; et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet: 2013; 382 9900 1249 1257
188. Brandt L. J. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol: 2013; 108 2 177 185
189. Khoruts A.; Dicksved J.; Jansson J. K.; Sadowsky M. J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol: 2010; 44 5 354 360
190. Petrof E. O.; Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology: 2014; 146 6 1573 1582
191. Brandt L. J.; Reddy S. S. Fecal microbiota transplantation for recurrent clostridium difficile infection. J Clin Gastroenterol: 2011; 45 (Suppl): S159 S167
192. van Nood E.; Speelman P.; Kuijper E. J.; Keller J. J. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill: 2009; 14 34 1 6
193. Gough E.; Shaikh H.; Manges A. R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis: 2011; 53 10 994 1002
194. Kassam Z.; Lee C. H.; Yuan Y.; Hunt R. H. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol: 2013; 108 4 500 508
195. Guo B.; Harstall C.; Louie T.; Veldhuyzen van Zanten S.; Dieleman L. A. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther: 2012; 35 8 865 875
196. Sofi A. A.; Silverman A. L.; Khuder S.; Garborg K.; Westerink J. MA, Nawras A. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand J Gastroenterol: 2013; 48 3 266 273
197. van Nood E.; Vrieze A.; Nieuwdorp M.; et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med: 2013; 368 5 407 415
198. Brandt L. J.; Borody T. J.; Campbell J. Endoscopic fecal microbiota transplantation: first-line treatment for severe clostridium difficile infection? J Clin Gastroenterol: 2011; 45 8 655 657
199. Trubiano J. A.; Gardiner B.; Kwong J. C.; Ward P.; Testro A. G.; Charles P. GP. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol: 2013; 25 2 255 257
200. Kelly C. R.; Ihunnah C.; Fischer M.; et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol: 2014; 109 7 1065 1071
201. Konijeti G. G.; Sauk J.; Shrime M. G.; Gupta M.; Ananthakrishnan A. N. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis: 2014; 58 11 1507 1514
202. Food and Drug Administration Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. July 2013. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm361379.htm
203. Hecht G. A.; Blaser M. J.; Gordon J.; et al. What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile Infection? Clin Gastroenterol Hepatol: 2014; 12 2 289 291
204. Bakken J. S.; Borody T.; Brandt L. J.; et al. Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol: 2011; 9 12 1044 1049
205. Hamilton M. J.; Weingarden A. R.; Sadowsky M. J.; Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol: 2012; 107 5 761 767
206. Youngster I.; Sauk J.; Pindar C.; et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis: 2014; 58 11 1515 1522
207. Adamu B. O.; Lawley T. D. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol: 2013; 16 5 596 601
208. de Vos W. M. Fame and future of faecal transplantations-developing next-generation therapies with synthetic microbiomes. Microb Biotechnol: 2013; 6 4 316 325
209. Tvede M.; Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet: 1989; 1 8648 1156 1160
210. Lawley T. D.; Clare S.; Walker A. W.; et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog: 2012; 8 10 e1002995
211. Petrof E. O.; Gloor G. B.; Vanner S. J.; et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome: 2013; 1 1 3
212. Allen-Vercoe E.; Petrof E. O. Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative. Expert Rev Gastroenterol Hepatol: 2013; 7 4 291 293
213. Kyne L.; Warny M.; Qamar A.; Kelly C. P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet: 2001; 357 9251 189 193
214. Bauer M. P.; Nibbering P. H.; Poxton I. R.; Kuijper E. J.; van Dissel J. T. Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin Microbiol Infect: 2014
215. Abougergi M. S.; Broor A.; Cui W.; Jaar B. G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med: 2010; 5 1 E1 E9
216. Humphreys D. P.; Wilcox M. H. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol: 2014; 21 7 913 923
217. Lowy I.; Molrine D. C.; Leav B. A.; et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med: 2010; 362 3 197 205
218. Leav B. A.; Blair B.; Leney M.; et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine: 2010; 28 4 965 969
219. Lee B. Y.; Popovich M. J.; Tian Y.; et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine: 2010; 28 32 5245 5253
220. Mizrahi A.; Collignon A.; Péchiné S. Passive and active immunization strategies against Clostridium difficile infections: State of the art. Anaerobe: 2014